Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma: an Observational, Real-world Study

NCT06333561 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06333561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06333561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma: an Observational, Real-world Study
Lead sponsor
Sun Yat-sen University
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2021
Completion date
December 30, 2025
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic arterial infusion chemotherapy, hepatocellular carcinoma, lenvatinib, pd-1 inhibitor